Marta Figueiredo, PhD, managing science editor —

A Phase 2 clinical trial evaluating Endeavor BioMedicines’ experimental oral therapy taladegib (ENV-101) in people with idiopathic pulmonary fibrosis (IPF), has dosed its first patient. The trial (NCT04968574) is enrolling adults, ages 40 and older, with mild-to-moderate IPF at one Australian site, with at least three more…

Adding co-trimoxazole or doxycycline — two broad-spectrum antibiotics — to standard care does not significantly slow lung function decline or prolong survival in people with idiopathic pulmonary fibrosis (IPF), a review study has found. This approach was instead associated with a higher risk of side effects, specifically gastrointestinal issues.

Blocking the activity of a cell death-suppressing protein called Bcl-2 promoted the death of macrophages — a type of immune cell involved in pulmonary fibrosis (PF) — and reversed established lung scarring in a mouse model, a study showed. Notably, Bcl-2’s anchoring at the surface of macrophage mitochondria was…

In preclinical studies, PRS-220, Pieris Pharmaceuticals’ experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab — an into-the-vein, mechanistically similar IPF therapy currently being tested in a Phase 3 clinical trial. These promising findings, which support Pieris’…

Treatment with vitamin D’s active form lessened lung scarring, and significantly reduced the levels of fibrotic markers in a mouse model of idiopathic pulmonary fibrosis (IPF), a study reported. Notably, these benefits were associated with vitamin D’s suppression of the renin-angiotensin system (RAS), whose chronic activation promotes the production of…

Six months of treatment with MN-001 (tipelukast), MediciNova’s investigational oral therapy, failed to significantly improve lung function in adults with idiopathic pulmonary fibrosis (IPF), according to data from a small Phase 2 clinical trial. The therapy, however, was associated with some positive effects, such as a reduction in worsening IPF…

A type 2 diabetes medication, metformin significantly eased lung inflammation and scarring (fibrosis) in a mouse model of silica-induced pulmonary fibrosis (PF), both at early and late stages of the disease. Notably, these benefits were found to be associated with a reduction in oxidative stress, inflammation, fibrotic markers, and…

Blocking the activity of a metabolic enzyme called succinate dehydrogenase (SDH) promoted the death of myofibroblasts — the main drivers of pulmonary fibrosis (PF) — and helped to heal persistent lung scarring (fibrosis) in a rat model, a study reported. These benefits were associated with a rescue of the metabolic abnormalities…

Researchers at the University of Alberta are studying whether combining a commercially available wearable device with artificial intelligence can effectively predict symptom worsening in people with chronic lung conditions, such as idiopathic pulmonary fibrosis (IPF). Developed by New York-based Health Care Originals to monitor asthma, the ADAMM-RSM…

Four months of treatment with Tyvaso (inhaled treprostinil) significantly improved lung function in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a post-hoc analysis of data from the Phase 2/3 INCREASE clinical trial. PH-ILD comprises a group of conditions characterized by significant lung scarring (fibrosis), including…